18-23-07

JEW -

Please type a plus sign (+) inside this box →

PTO/SB/21 (05-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork	Reduction Act of 1995, no	persons are required	to respond to a collection of inf	ormation unless it displays a valid OMB control number.
SIPE			Application Number	10/561,583
E TDA	NICHAITTAI		Filing Date	March 15, 2007
2 1 2007 THA	NSMITTAL	-	First Named Inventor	VAN WAMEL, WILLEM JAN BASTIAAN
.6	FORM		Group Art Unit	Not yet assigned
DEMARKS to be used for a	ll correspondence after ini	tial filing)	Examiner Name	Not yet assigned
	of Pages in This Submissi	3	Attorney Docket Number	ARSI-012
TOISTTOMOCIT	or ragos in this coomissi		ES (check all that apply)	
Extension of T Express Aban Information Statement SB08A F Certified Copy Documents	ched Reply tal sidectaration(s) Time Request domment Request Disclosure orm (total 2 pgs.) of Priority	(for an Drawir   Drawir   Licens   Petitio   Petitio   Provisi   Power   Chang Addret   Termir   Power   Termir   Power   Po	ing-related Papers  n  n to Convert to a onal Application of Attorney, Revocation e of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Molice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 6 References Return Postcard
		CD, Ni Remarks	umber of CD(s	Y .
	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OF	RAGENT
Signing Attorney/Agent (Reg. No.)	CAROLL FRANCI BOZIGEVIC, FIELD	S, PH.D., 36,513		
Date	August 21, 2007			
	FX	PRESS MAIL L	ABEL NO. EV 95401152	2115

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to lie (lead by the USPTO) or process) an application. Confidentiality is governed by 38 U.S. C. 122 and 57 CFR 1.1. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the mount of time you require to complete the form and/or surgessens for revoking the burden, should be sent to the Cfrei information Officer, U.S. Petent and Tademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, V.A. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissionary for Patients, P.O. Box 1450, Alexandria, V.A. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## Express Mail No. EV 954011522 US

CHARLEMAN .		Linevale	
INFORMATION	Attorney Docket	ARSI-012	
DISCLOSURE STATEMENT	First Named Inventor	VAN WAMEL, WILLEM JAN	
	Application Number	10/561,583	
Address to:	Confirmation No.	6152	
Mail Stop	Filing Date	March 15, 2007	
Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Group Art Unit	Not yet assigned	
	Examiner Name	Not yet assigned	
	Title: "THERAPEUTIC USE OF LPI, A STAPHYLOCOCCAL LECTIN PATHWAY INHIBITOR IN INFLAMMATORY DISEASES"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. ARSI-012 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Registration No. 36,513

By: Carol I. Francis Ph.D.

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

PTO/SB/08a (09-06) Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

d to respond to a collection of information unless it contains a valid OMB control number. PADEMAN Complete if Known Substitute for form 1449A/PTO Application Number 10/561,583 INFORMATION DISCLOSURE Filing Date March 15, 2007 STATEMENT BY APPLICANT First Named Inventor VAN WAMEL, WILLEM JAN BASTIAAN Art I Init Not yet assigned Examiner Name Not yet assigned (Use as many sheets as necessary) Attorney Docket Number Sheet of ARSI-012

AUG 2 1 2007

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials'	No.'	Number-Kind Code <sup>2</sup> (if known,	,	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
		US-							
		US-							
		US-				15-			

		FOREIG	N PATENT DO	CUMENTS		
Examiner Initials'	Cite No.1	Foreign Petent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		EP-A-0 786 519	07/30/1997	Human Genome Sciences, Inc.		
		WO 94/06830 A	03/31/1994	Alfa Laval Agric Int AB		
		WO 02/094868	11/28/2002	Chiron SPA		
		WO 2004/087746 A2	10/14/2004	Intercell AG		
		·				

Exam include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bo magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city an country where published.  KURODA et al. Whole genome sequencing of meticillin-resistant staphylococcus aureus. Lancet, 2001, vol. 357, pss. 1225-1240 XP0004246103  DATABASE UniProt [Online] 1 Dec. 2001, "Hypothetical protein." XP002322488, retri		
Lancet, 2001, vol. 357, pgs. 1225-1240 XP004246103		T²
DATABASE UniDeat [Online] 1 Dec. 2001 "Hymothetical protein." VD002222409 setti	The	
from EBI accession no. UNITPROT:Q931 M7	rieved	

		DATABASE UniProt [Online] 1 De from EBI accession no. UNITPROT:	Il protein." XP	)02322488, retrieved	
xaminer	/	Patricia Duffy/	Date Considered	06/08/2010	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.